DDInter1505 DDInter690
Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a _non-ergot dopamine agonist_ drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement). It was first approved by the FDA in 1997. Parkinson's Disease is one of the most common neurodegenerative disorders and causes a high level of disability in patients, leading to increased difficulty in performing activities of daily living due to symptoms that progress over time. The prevalence of Parkinson's Disease worldwide has increased from approximately 2.5 million in 1990 to about 6.1 million in 2016. This increase may be attributed to an aging population along with other contributing factors. In addition to the above FDA approval for Parkinson's Disease, pramipexole was also approved by the FDA in 2006 for the treatment of Restless Legs Syndrome (
A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in alcoholic beverages.
Pramipexole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diphenhydramine
Diphenhydramine {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Ethanol
Pramipexole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ranitidine
Ranitidine {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Ethanol
Pramipexole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clemastine
Clemastine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ethanol
Pramipexole {u} (Compound) palliates {v} (Disease) Parkinson's disease
Parkinson's disease {u} (Disease) is associated with {v} (Gene) CYP2E1
CYP2E1 {u} (Gene) is bound by {v} (Compound) Ethanol
Pramipexole {u} (Compound) binds {v} (Gene) DRD4
DRD4 {u} (Gene) interacts with {v} (Gene) GABRA1
GABRA1 {u} (Gene) is bound by {v} (Compound) Ethanol
Pramipexole may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Ethanol (Compound)
Pramipexole may cause a minor interaction that can limit clinical effects when taken with Ranitidine and Ranitidine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Ethanol (Compound)
Pramipexole may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ethanol (Compound)
Pramipexole (Compound) palliates Parkinson's disease (Disease) and Parkinson's disease (Disease) is associated with CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Ethanol (Compound)
Pramipexole (Compound) binds DRD4 (Gene) and DRD4 (Gene) interacts with GABRA1 (Gene) and GABRA1 (Gene) is bound by Ethanol (Compound)